Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chartwell Molecular
- Ownership
- Private
- Development stage
- Other
01
Overview
Chartwell Molecular has multiple approved small molecule drugs including morphine sulfate for acute and chronic pain, metolazone for hypertension and edema, acyclovir for viral infections, and others. Products are approved and marketed, with opioids as a primary focus. The company is primarily engaged in commercial generic/small molecule drug development and supplying approved drugs. Some product NDAs originally filed pre-2010 are now discontinued or generic.
- Therapeutic areas
- CardiovascularRheumatologyInfectious DiseasesNeurologyOtherPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Chartwell Molecular.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chartwell Molecular.